Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $12.37
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Oct 9, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 15, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 15, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Apr 6, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Oct 3, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 16, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jul 16, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Apr 7, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 41.74 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 29.23 | Oscillator | Neutral |
| Williams %R (14) | -65.28 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.88 (Hist 0.04) | Oscillator | Buy |
| Average Directional Index (14) | 42.18 (+DI 15.2 / -DI 27.3) | Trend | Strong Sell |
| EMA 20 | 12.72 | MA | Sell |
| SMA 20 | 12.97 | MA | Strong Sell |
| EMA 50 | 13.71 | MA | Strong Sell |
| SMA 50 | 14.55 | MA | Strong Sell |
| SMA 200 | 12.42 | MA | Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | ANGO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -15.7x | -12.4x · sector 20.7x | Discount |
| Forward P/E (FY27E) | -45.3x | EPS est. -0.27 | Elevated |
| Price / Book | 3.2x | 1.8x | Elevated |
| Price / Sales | 1.6x | 1.4x | In line |
| EV / EBITDA | -50.3x | 220.8x | Discount |
| Return on equity | -19.2% | — | Weak |
| Gross margin | 55.7% | 52.7% | In line |
| Debt / Equity | 0.07 | 0.07 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 2.58 | Grey zone |
Discounted cash flow model
FY2024 · 10-K disclosure
FY2026 · 10-K disclosure
| 8-K | Oct 8, 2026 | 2026-10-08 07:16:17 | View |
| 10-K/A | Sep 29, 2026 | 2026-09-29 16:01:59 | View |
| 10-K/A | Sep 29, 2026 | 2026-09-29 09:14:18 | View |
| 4 | Jul 31, 2026 | 2026-07-31 16:45:07 | View |
| 4 | Jul 24, 2026 | 2026-07-24 18:10:55 | View |
| 4 | Jul 24, 2026 | 2026-07-24 18:10:54 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jul 30, 26 | Nighan Warren Jr | officer: SVP Quality and Regulatory | S-Sale | 23,370 @ $14.72 | $344.0K |
| Jul 22, 26 | Piccinini Laura | officer: SVP International | M-Exempt | 8,047 | — |
| Jul 22, 26 | Piccinini Laura | officer: SVP International | F-InKind | 4,506 @ $13.82 | $62.27K |
| Jul 22, 26 | Piccinini Laura | officer: SVP International | M-Exempt | 28,336 | — |
| Jul 22, 26 | Nighan Warren Jr | officer: SVP Quality and Regulatory | M-Exempt | 5,694 | — |
| Jul 22, 26 | Nighan Warren Jr | officer: SVP Quality and Regulatory | F-InKind | 1,671 @ $13.82 | $23.09K |
| Jul 22, 26 | Nighan Warren Jr | officer: SVP Quality and Regulatory | M-Exempt | 20,052 | — |
| Jul 22, 26 | Trowbridge Stephen A | officer: EVP and CFO | M-Exempt | 16,296 | — |
Stock news · updated daily
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in.
AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec.
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 8, 2026 | -0.11 | -0.04 | Beat 64.4% | $80.92M |
| Jul 14, 2026 | -0.11 | -0.07 | Beat 36.4% | $86.61M |
| Apr 2, 2026 | -0.11 | -0.07 | Beat 36.4% | $78.42M |
| Jan 6, 2026 | -0.10 | -0.15 | Miss -50.0% | $79.43M |
| Oct 2, 2025 | -0.14 | -0.10 | Beat 28.6% | $75.71M |
| Jul 15, 2025 | -0.13 | -0.03 | Beat 76.9% | $80.16M |